ImpediMed Limited
IPDQF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $12,724 | $10,053 | $11,344 | $10,495 |
| % Growth | 26.6% | -11.4% | 8.1% | – |
| Cost of Goods Sold | $1,749 | $1,314 | $24,998 | $1,709 |
| Gross Profit | $10,975 | $8,739 | -$13,654 | $8,786 |
| % Margin | 86.3% | 86.9% | -120.4% | 83.7% |
| R&D Expenses | $0 | $221 | $598 | $683 |
| G&A Expenses | $21,513 | $22,095 | $19,506 | $18,154 |
| SG&A Expenses | $22,312 | $22,619 | $19,964 | $18,823 |
| Sales & Mktg Exp. | $799 | $524 | $458 | $669 |
| Other Operating Expenses | $12,894 | $0 | $1,703 | $1,691 |
| Operating Expenses | $35,206 | $33,043 | $9,192 | $30,323 |
| Operating Income | -$24,231 | -$24,304 | -$22,846 | -$21,537 |
| % Margin | -190.4% | -241.8% | -201.4% | -205.2% |
| Other Income/Exp. Net | $1,020 | $4,547 | -$2,483 | -$2,526 |
| Pre-Tax Income | -$23,211 | -$19,757 | -$22,076 | -$19,828 |
| Tax Expense | $26 | $33 | -$1,555 | $46 |
| Net Income | -$23,237 | -$19,790 | -$20,521 | -$19,874 |
| % Margin | -182.6% | -196.9% | -180.9% | -189.4% |
| EPS | -0.012 | -0.01 | -0.011 | -0.012 |
| % Growth | -17.3% | 14% | 3.4% | – |
| EPS Diluted | -0.012 | -0.01 | -0.011 | -0.012 |
| Weighted Avg Shares Out | 2,019,175 | 2,021,741 | 1,800,349 | 1,678,954 |
| Weighted Avg Shares Out Dil | 2,019,175 | 2,021,741 | 1,800,349 | 1,678,954 |
| Supplemental Information | – | – | – | – |
| Interest Income | $960 | $1,559 | $801 | $46 |
| Interest Expense | $1,094 | $93 | $34 | $28 |
| Depreciation & Amortization | $4,564 | $2,253 | $2,467 | $2,769 |
| EBITDA | -$17,553 | -$22,051 | -$20,493 | -$18,768 |
| % Margin | -138% | -219.3% | -180.7% | -178.8% |